Timothy Sterling Archive — Page 1 of 1

White, black, and pink pills arranged to form a pair of lungs on a light blue background.
December 1, 2025

Timothy Sterling receives $5.7 million to study tuberculosis transmission

Using molecular and other data from both the bacterial and human sides of the equation, a multi-institutional team will develop prediction models of TB transmission.

By Paul Govern
A hand reaches upward beneath a glowing, detailed Earth centered on Europe, Asia, and Africa, set against a star-filled blue-black background.
June 14, 2023

NIH grant boosts international TB research consortium

A new grant will help support Vanderbilt’s RePORT Brazil, one of an international consortium’s six regional tuberculosis research programs.

By Paul Govern
Head-and-shoulders portrait of Timothy Sterling, MD, wearing glasses, a dark suit, white shirt, and patterned red tie.
February 23, 2023

NIH grant supports TB research network in Brazil

The National Institutes of Health has awarded a five-year, $5 million grant to Vanderbilt University Medical Center for continued support of the Brazil Regional Prospective Observational Research in Tuberculosis network, or RePORT-Brazil.

By Paul Govern
Portrait of Timothy R. Sterling, M.D., wearing glasses, a suit, and tie against a neutral background.
November 10, 2016

Grants enhance Tuberculosis Center’s global research efforts

Since July, investigators in the Vanderbilt Tuberculosis Center have been awarded research grants totaling $5 million.

By Paul Govern
Man holds his hand over his mouth while coughing into it
August 4, 2016

HIV treatment and TB risk

Tuberculosis (TB) remains an important public health problem, particularly among people infected with the human immunodeficiency virus (HIV).

By Bill Snyder
Open orange prescription bottle lying on its side with numerous green-and-white capsules spilled onto a white surface.
October 30, 2013

Preserving antibiotic arsenal for TB

Clinicians should be cautious about prescribing newer fluoroquinolone antibiotics to patients with TB risk factors; doing so may jeopardize the use of these agents against TB.

By Leigh MacMillan